UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 3,041	$ 3,956
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	200	156
Amortization	509	513
Provision for losses on/(recovery of) accounts receivable	(9)	(8)
Amortization of Right-of-Use Assets	12	14
Deferred income taxes	(209)	(192)
Stock-based compensation expense	82	79
Tax benefit attributable to exercise of stock options	0	9
Accounts receivable and other receivables	12	(214)
Inventories	275	271
Prepaid expenses and other current assets	(26)	(87)
Accounts payable	217	230
Accrued expenses	360	549
Total adjustments	1,423	1,320
Net cash provided by operating activities	4,464	5,276
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(184)	(22)
Proceeds from sale of equipment	0	27
Net cash provided by/(used in) investing activities	(184)	5
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	0	96
Common stock purchased and retired	(3,221)	(2,990)
Payment of dividends	(1,017)	(1,089)
Net cash used in financing activities	(4,238)	(3,983)
Effect of exchange rate changes on cash	307	(358)
Net increase in cash and cash equivalents	349	940
Cash at beginning of period	82,976	92,868
Cash at end of period	83,325	93,808
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for income taxes	46	105
Cash paid during the period for interest	$ 0	$ 0